Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Z-VAD-FMK Chemical Structure

Z-VAD-FMK Chemical Structure
Molecular Weight: 467.49

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Product Information

  • Compare Caspase Inhibitors & Activators
    Compare Caspase Products
  • Research Area

Product Description

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Targets Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
GC1aNWjheWlvSXCxcITvd4l{KEG|c3H5NUPONZhpPTEQvF2=NYHGcFVMOjSqM2i5eolv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRmM2\MU|I3OTZ7MEe1
HGL5MXnBdI9xfG:|aYOgRZN{[Xl?MmjrOVDPxE1?MV[yOIg>MkLjbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU>NYricJdKOjZzNkmwO|U>
HepG2MXfBdI9xfG:|aYOgRZN{[Xl?NYqzVVlsOjEQvF2=MWexbC=>MV\heJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMgNF:4c5QzPjF4NEe5OS=>
BEL-7402NGjye|RCeG:ydH;zbZMhSXO|YYm=M{fnWVIx|ryPNIq4NFgycA>?NECwNnlifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKhNHf5dY0zPjF4NEe5OS=>
CEFM2jXfWtqdmG|ZTDBd5NigQ>?MlP6NEw{Oyx4NzyxNFDPxE1?NXWxO41oOTWvaX6=Mknr[I94di2{ZXf1cIF1\XNiUGKg[Y57gW2nIHHjeIl3cXS7IITvJFQx97zHIHH0JFExOM7:TR?=NV;LN|VtOjZzMEKzN|k>
SP2/0M2LKSGFxd3C2b4Ppd{BCe3OjeR?=NVrURZNzOTByzszNNHu4cnoycA>?MXTEUXNQNFyx[2RjdG:la4OgeIhmKGGyb4D0c5NqeyCxZjDTVFIwOCClZXzsdy=>MkPpNlYxPzR5M{K=
HUVEC-2cNXXEcnhYSXCxcITvd4l{KEG|c3H5MmOyOVDPxE1?NWfLfY83Pmh?NHvBTWNl\WO{ZXHz[YQhfGinIH;4MWxFVC2rbnT1Z4VlKGG3dH;wbIFogQ>?MoW4NlYxOjF5Mkm=
U1MVfBdI9xfG:|aYOgRZN{[Xl?MVWwMVExOM7:TR?=Mn\RNog>MVLy[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NUPjZ49lOjV7OEC5OFI>
ACH-2M3fOZWFxd3C2b4Ppd{BCe3OjeR?=M4jFelAuOjByzszNNUjhN4szOmh?NF\hO5dz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>MYeyOVk5ODl2Mh?=
U1NWizbVlyU2mwYYPlJGF{e2G7MlrtNVAx|ryPNXzBUoh[Omh?MUHpcohq[mm2czDjZZNx[XOnLUO=MkPuNlU6QDB7NEK=
A549/V16M4nnTGFxd3C2b4Ppd{BCe3OjeR?=MnXMOVDPxE1?NHjxTncycA>?Mm[5doVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m|MnTRNlU6PDZyM{O=
SGNNVnRdnlMSXCxcITvd4l{KEG|c3H5NUjXNmpKOjCvTR?=NILZdIc1QGh?NVy2WnlWcGG|IH7vJIlv\my3ZX7j[UBwdiCDSV[sJINidHCjaX6g[ZhxemW|c3nvckBweiClZXzsJIFxd3C2b4Ppdy=>MVuyOVg4PDZ|Mx?=
HCT116 M3HYPWFxd3C2b4Ppd{BCe3OjeR?=M37pUVUx|ryPNUfuepZnOmh?M13HWolvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>?M2jPblI2QDZ6OEG4
DTK-SMEMYnBdI9xfG:|aYOgRZN{[Xl?M3XpSVUx|ryPNYPpPIdtOmh?MlzKSG1UVw>?M1K1WJBienSrYXzsfUBqdmirYnn0d{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZpVxcX[jY3HpcoU>NUPWdWZFOjV6NEO4PVc>
HL-60MX\BdI9xfG:|aYOgRZN{[Xl?M3fMW|Ux|ryPNHjkfHM1QGh?NE\PbItz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>?M1XNWFI2QDJ2MESz
U937NYXmSm1sSXCxcITvd4l{KEG|c3H5MV[1NO69VQ>?MWm0PIg>MUDy[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=>NXrQclJEOjV6MkSwOFM>
A549Mk\3RZBweHSxc3nzJGF{e2G7NITTOoszOCEQvF2=Mof0NlRpNV\lbJo3emWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCKRlPQJJRz\WG2bXXueC=>M1zuUFI2Pzl2MUS5
HeLaMlzNRZBweHSxc3nzJGF{e2G7M2PZZVEx|ryPM3KxSVQ5cA>?MXTk[YNtcW6nczD0bIUhemG2ZTDv[kBieG:ydH;zbZMh\HKjbXH0bYNidGy7MkCwNlU4PzJ3NEW=
SGC-7901NWfKNm5ESXCxcITvd4l{KEG|c3H5NWXWfFRuOjEEoN88US=>MYGxbC=>NETBNWdqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JI95[WyrcHzheIlvMlPXNlU4PjdyN{[=
MCF-7M3fUNmFxd3C2b4Ppd{BCe3OjeR?=MYOxNO69VQ>?NIH6fYIzcA>?MVPpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IEPCM{DPXFI2PzJ{MUG0
A549NF3aR21CeG:ydH;zbZMhSXO|YYm=NX61WWh6OTBizszNNVfTe5NSOjSqM1zUNGROW09?NXT4VpBOeHKxbX;0[ZMhUEKFLYTy[YF1\WRiQUW0PUBk\WyuIIP1dpZqfmGuID[gZZR1\W63YYTld{B1cGViY3zlZZZm\CCSQWLQJIV5eHKnc4Ppc44>MVWyOVY5OzV4OB?=
U87MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\le|Ux|ryPNIHEN|kycA>?NVOyUZF3emWlb4\ldpMh[2WubDDndo94fGhiZoLvcUBVVVpidILlZZRu\W62MlLCNlU3QDF4Nki=
Neocortical NeuronM3rDXm5mfXKxdH;4bYNqfHliQYPzZZk>Mn7BNVAx|ryPNIriTG0ycA>?MlmwZY51[Wexbnn6[ZMhUG:rYX3p[IUhSS2LbnT1Z4VlKE6ndYLveI95cWOrdIm=M2rx[lI2Pjd3MECx
Primary human placental cytotrophoblastsNGfZc3hCeG:ydH;zbZMhSXO|YYm=M1:x[VMx|ryPNFPRUnYzPGh?MlTrSG1UVw>?NYHjXohzemW4ZYLz[ZMhfGinIHnubIljcXSrb36gc4YhOTIQsj3IV2QzKGK7IITybYNtd3OjbtMgNYLjNHZSOjV4NEK1PVI>
MMMontRZBweHSxc3nzJGF{e2G7NFfacZE2OM7:TR?=NWfKWlIxOjCvaX6=NGXCNoJx[XK2bImgbY5pcWKrdIOgV2hMNWmwZIXj[YQhKGOnbHyg[IVifGh?NV7DNZcxOjV3M{CwPVg>
DLD1NIL4N4hCeG:ydH;zbZMhSXO|YYm=MWSyNOKh|ryPNXixU5JsOWh?NUTOOIZ6eGG{dHz5JJJmfmW{c3XzJINmdGxiYYDvdJRwe2m|IHPheZNm\CCkeTDXV3AyMYKyOVUzPDJ2Nh?=
MDA-MB-231NEm4dHVEgXSxdH;4bYNqfHliQYPzZZk>M{PBVVEx|ryPMVOxbC=>NInjWG9ifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62M2PMTVI2PTJzNUCx
MKN28NIn1RnpCeG:ydH;zbZMhSXO|YYm=NFj6NmMyOM7:TR?=NUTldpJlOzCvaX6=M4PIbGROW09?M1mzZ4lvcGmkaYTzJHRPTi4QsTDwcJV{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?=M1\Bd|I2PTF|OU[w
HL-60MV7DfZRwfG:6aXPpeJkhSXO|YYm=NITuWGUyODEQvF2=Mn7mNYg>NF6wWVRFVVORMYlCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy|NUnkO2JjOjV3MEK5N|I>
AGSNH\v[3dCeG:ydH;zbZMhSXO|YYm=MoLsNVDPxE1?M2HMbVFpMWDwdoV3\W62czDjeZJkfW2rbj3pcoR2[2WmIHPs[YF3[WenIH;mJINie3Cjc3WtN{whNThuIHHu[EAuQSCycn;0[Ylvew>?NGXBPYUzPTR7MkKxOC=>
A549 M2TVdGFxd3C2b4Ppd{BCe3OjeR?=M1vPVVEx|ryPMnXUNlRpMVzicI9kc3NiRF3BV{1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCjbnSgZZBweHSxdHnjJINmdGxiZHXheIg>M{LBeVI2PDN2OUi5
INS-1NUjuSpJxSXCxcITvd4l{KEG|c3H5NFi0WFY2OM7:TR?=NHrpT|k3cA>?MUnEUXNQM1Lmd4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBm[XKueTDhdI9xfG:2aXOgZ4VtdHQEoB?=NHTPcmkzPTR|MEi5Oy=>
Primary hepatocytes M13OdGFxd3C2b4Ppd{BCe3OjeR?=MlHJOVDPxE1?MVixPIg>Mnz0bY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?=NFX6dXozPTRyN{WzPC=>
L929-A NXr6O3M{S3m2b4TvfIlkcXS7IFHzd4F6NXXHfmZYOjEEoN88US=>M{DoblI1cA>?M37LW4lvcGmkaYTzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?=NX7JSlV1OjV|OUi1OFA>
L929-NM1faeGN6fG:2b4jpZ4l1gSCDc4PhfS=>MUWyNOKh|ryPNVTLS3pUOjSqM{nQOIVvcGGwY3XzJIRm[XSqII\pZUBifXSxY4LpcoUhXE6IzsGgdJJw\HWldHnvci=>NGXUcGozPTN7OEW0NC=>
Cytotoxicity AssayNWXxbZNGS2WubDDWbYFjcWyrdImgRZN{[Xl?NWrCVXNtOjEQvF2=MlfIOFhpNWHGSFI3eHKndnXueEBOUE2GLXnu[JVk\WRiY3XscEBl\WG2aB?=MX[yOVM6OjFzNh?=
COS7MlO2T4lv[XOnIFHzd4F6MVixNO69VQ>?NUP2PFUxOjSqNGDpdlFqdmO{ZXHz[ZMh[2G|cHHz[UA{NzdiYXP0bZZqfGmncx?=NHfYeWIzPTN6NECyOS=>
COS7NW\n[4htSXCxcITvd4l{KEG|c3H5NV2xN3hpOTEQvF2=MW[0PIg>M37GWZBienSrYXzsfUBxemW4ZX70[YQhTkNzMEGtbY5lfWOnZDDj[YxtKGSnYYToNX;weFF7OjV|OESwNlU>
A375NIXmWXpCeG:ydH;zbZMhSXO|YYm=MWWzNO69VQ>?M2XnV|JpNHu4b5BxemW4ZX70d{B1cGViZIL1[{1qdmS3Y3XkJHBCWlBiY3zlZZZi\2V?M3v3XFI2Ozd4MUG1
A549NHfJWYpCeG:ydH;zbZMhSXO|YYm=MWW1NO69VQ>?MVeyOIg>MnjPdoV3\XK|ZYOgdoljd3OxbXWgZolw\2WwZYPpd{BidmRiYYDvdJRwe2m|IHPheZNm\CCkeTCgR4hqcm:wZ3Thci=>NX\NTmRGOjV|NEm3PFE>
A549NEPDNppCeG:ydH;zbZMhSXO|YYm=NW\0eINHOi53LUK1{txOM1ziNlFpMoPs[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN?Ml;rNlU{PDJ2Mke=
 NBL-W-S NE\FTnRCeG:ydH;zbZMhSXO|YYm=MX[1NO69VQ>?M17BR|FpMniz[pVtdHlicnXzZ5VmeyClZXzsJJZq[WKrbHn0fUBi\nSncjDHRW5VNTZzIITy[YF1dWWwdB?=M1jRclI2OzJ|MkKy
Caki-1 MV;BdI9xfG:|aYOgRZN{[Xl?NU[4O2hvPDEQvF2=NULtOIQ5PDiqNITQOY1z\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{M2m0[FI2Ojd7MUmx
769-PNXviOohXSXCxcITvd4l{KEG|c3H5MX60NO69VQ>?MVO0PIg>M1XYUpJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM>MYqyOVI4QTF7MR?=
H9c2M{j4fWFxd3C2b4Ppd{BCe3OjeR?=MVW1NO69VQ>?MmnINYg>MkSzbY5pcWKrdIOgSG9ZNWmwZIXj[YQh[2G|cHHz[UA{KGGldHn2ZZRqd25iYoX0JI5wfCC2aHWgcI9{eyCxZjDj[Yxtew>?MW[yOVI5OzhzOR?=
K562M4TkPGFxd3C2b4Ppd{BCe3OjeR?=NWr5SpZkPTEQvF2=MnPDOIg>NGO0do5qdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{Ml\INlUzPDF4MUm=
L929MkjxRZBweHSxc3nzJGF{e2G7NVvXPJBIOTEQvF2=M2TQ[VZpMXTpcoR2[2W|IH7lZ5JweHSxc3nzJJdqfGhiVF7GNFz3V4MzPTF7NU[2NC=>
A549MWjBdI9xfG:|aYOgRZN{[Xl?NWLJ[m9LOTEQvF2=M{jQb|NpMoj6doVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHRMnfxNlUyPjF4OUm=
MCF-7MX7BdI9xfG:|aYOgRZN{[Xl?NH[xSG4zOM7:TR?=NIC3cWUzcA>?NWXy[mtR\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>?NH7afowzPTF6MkK0NC=>
OSMWPBdI9xfG:|aYOgRZN{[Xl?M1vvbFIxNzRyzszNMXO3Nog>NFy4cGFqdmirYnn0d{BQWyClZXzsJJZq[WKrbHn0fUBz\WS3Y4Tpc44h[nliQ{[gZ4Vz[W2rZHW=NXLxTZlNOjVzNUKzPVk>
HUVECsM3vGPGFxd3C2b4Ppd{BCe3OjeR?=MXWxNO69VQ>?MYqybC=>MlyzxsBqdmirYnn0d{BieG:ydH;zbZMh[W6mIH\hZ4ltcXSjdHXzJIF2fG:yaHHnfUBqdiCGRV7WNk1qdm[nY4Tl[EBJXV[HQ4O=MkjJNlUyOzh5MEO=
EA.hy926MYTBdI9xfG:|aYOgRZN{[Xl?NVfnb|RKOTEQvF2=M176Z|JpM3TT[uKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY>MViyOVE{QDdyMx?=
EbsNYS4Snd7SXCxcITvd4l{KEG|c3H5M{jWSVExNTFyMN88US=>MlqyNlRpNY\Q[4Z1yqCPTWTTJIdmdmW{YYTpc44hemG2ZTDk[YNz\WG|ZXSgZZMhfGinIHPvcoNmdnS{YYTpc44hd2Ziej3WRWQv\m2tIHnuZ5Jm[XOnZB?=NGnDW3IzPTF|NEixOy=>
JurkatNEPXbnlCeG:ydH;zbZMhSXO|YYm=NGL4fVkzOM7:TR?=MVeyOIg>MnjrSG1UVw>?MUfwZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA>Mmn2NlUyOjB5MkO=
K562M4TQUGFxd3C2b4Ppd{BCe3OjeR?=NVu2UZlYOC5zLUJOwG0>NYfHcIY2OWh?Mlf4bY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=MnrwNlUyOTlzOEi=
IMR-32M32zRWFxd3C2b4Ppd{BCe3OjeR?=MUm0NOKh|ryPwrC=MlX5Nog>MWPk[YNz\WG|ZTDpckBieG:ydH;0bYMh[2WubIOgZ49ueGG{ZXSgeI8hXC1{IITvfIlvMnjmNlUxQDR5NUW=
RPMI 8226M4jtUmFxd3C2b4Ppd{BCe3OjeR?=M1[1WFExOM7:TR?=M1zZPFFpNX\G[HJ2[Wyvb4P0JINwdXCuZYTlcJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG=M3vHW|I2ODN5OEWx
U266 MnLTRZBweHSxc3nzJGF{e2G7NIK0dIMyODEQvF2=MYixbC=>MmH2dIFzfGmjbHz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1zMYmyOVA{Pzh3MR?=
H929 MXXBdI9xfG:|aYOgRZN{[Xl?MoSxNVAx|ryPNYrPZ|VnOWh?NVHse5dqeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2xNFPNS|kzPTB|N{i1NS=>
MM.1S M1HISWFxd3C2b4Ppd{BCe3OjeR?=MXexNFDPxE1?NXXWcWVIOWh?Mln5[YZncWOrZX70cJkheHKndnXueJMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDDk[YF1cCClb33ibY5mKHerdHigcoVkem:|dHH0bY4uOQ>?MX2yOVA{Pzh3MR?=
C6NGqxTWhCeG:ydH;zbZMhSXO|YYm=MYS1NO69VQ>?NH3ve441QGh?NFL3SYNxemW4ZX70d{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBk[XW|ZXSgZpkheHKnZ37lco9td26nMXmyOVAyOzR5OR?=
AGSNX\EbYZ6SXCxcITvd4l{KEG|c3H5MWS1NO69VQ>?NUfGb|RYOjSqM{jHbIFjd2yrc3jzJO6zNWyjcHHjbI9v\S2rbnT1Z4VlKGOnbHyg[IVifGhiYX7kJIlvcGmkaYTl[EBoem:5dHi=NHTndnQzPTByOU[5PC=>
HeLa NVi5e2ROSXCxcITvd4l{KEG|c3H5NYLvPYllPDEQvF2=NYOxeFJ5OjSqNX;Qb4l3cW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDhdI9xfG:|aYOgbY5lfWOnZDDifUB{cVKQRkGyNS=>NUjwc3d4OjR7Mki2PFU>
THP-1 NVrufmJjSXCxcITvd4l{KEG|c3H5NXzMW3hxOTEQvF2=M{W3XFFpNEXVb3hz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEGOQT3TSHTDqA>?NIjwcG8zPDl{M{[1Ny=>
P815 NUHtSWNmSXCxcITvd4l{KEG|c3H5NHi0TIgyODBiwsXNMXixNog>NWTMeZFRTE2VTx?=MVTpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>?MorLNlQ6OjN{N{O=
HCT116M2HZeGFxd3C2b4Ppd{BCe3OjeR?=M2jNSVIx|ryPM3;aSVI1cA>?NICyTlBi[nKxZ3H0[ZMhd2ZiVGGtbY5lfWOnZDDhdI9xfG:|aR?=NWTMb2lSOjR6OUC0OFk>
SW1116 MVLBdI9xfG:|aYOgRZN{[Xl?NFrib4cyOCEEtV2=MkXVNYg>NXnzNml1TE2VTx?=MYLy[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6nMl\PNlQ5PzR{OE[=
LOVOMkXXRZBweHSxc3nzJGF{e2G7NV\vNXN6OTBiwsXNNVS1cHdROWh?M4q2bmROW09?MV\y[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6nMl3ENlQ5PzR{OE[=
SNU449 NFvvXWZCeG:ydH;zbZMhSXO|YYm=NXPJVGpVOjEQvF2=NISyVJM1QGh?NXzmS|NrTE2VTx?=MU\k[YNz\WG|ZYOgcYlTNTR3MT3pcoR2[2WmIHHwc5B1d3SrYx?=NF;vN3EzPDh2MU[zPC=>
Caco-2NYPKTVJTSXCxcITvd4l{KEG|c3H5M1;nOVQx6oDLzszNNVT2UI1tPGh?NGTIXlRxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>?MkfBNlQ5OjJzOEO=
macrophageNVG4N2ZiS2WubDDWbYFjcWyrdImgRZN{[Xl?M1X0VlAuOjByzszNNXzuXGtsOjSqNHfPVnZqdmS3Y3XzJHRPTi1iYX7kJHJqeDNvZHXw[Y5l\W62IH7lZ5JweHSxc3nzJIlvKG2jY4LvdIhi\2V?M{fwT|I1Pzl7NU[1
AGS NX\RN|lrSXCxcITvd4l{KEG|c3H5M2nNb|Ix|ryPMUGxNog>MX7EUXNQMXLy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJJJme3CxboPlJJRwKHSqZTDFeG9C[yCocnHjeIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?M2f1OlI1Pzh7N{Cz
LCC9 NFy1T2lE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NI\wU4QyODEQvF2=M3XnUFVlM4mxfYJtd2OtczDj[YxtKGSnYYToJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25iTEG3JIFv\CClaHzvdo9yfWmwZR?=NXvVPGc3OjR5OEWyOVY>
U937 M{i1d45m[3KxcITvd4l{KEG|c3H5NGDoVocyOMLizszNNHP3SGs{OMLibXnuNWjNU|VkcW6mdXPld{Bv\WO{b4D0c5NqeyClb33ibY5mKHerdHigWG5HNWC4NYd{OjR5N{O3OVY>
T cellMX7D[YxtKHC{b3zp[oVz[XSrb36gZZN{[Xl?MXWwMVExOM7:TR?=NHviN5k4Omh?MnewTWM2OD15MDFOwG0tKGmwaHnibZR{KGGwdHmtR2Q{NWmwZIXj[YQhXCClZXzsJJBzd2yrZnXyZZRqd25iaX6gVGJOS3N?MlnqNlQ4Pjh5MEe=
HeLa NU\PTFVCSXCxcITvd4l{KEG|c3H5NWja[Y5LPTEQvF2=M4G1UlczcA>?M3vmWmROW09?MlvDdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2:vcH;1coR{yqBz4pETOS=>NUfwU5FOOjR5NUS3PFY>
HeLa MnPPRZBweHSxc3nzJGF{e2G7NV32b5JrOTByzszNM1SzUlI1cA>?NYTOOHhbe3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB?NF;QTJkzPDd{MkS2PC=>
IEC-6 NUnueWFwSXCxcITvd4l{KEG|c3H5MVyxNO69VQ>?MWqyOIg>NF34blNxemW4ZX70d{BV[2SDLXnu[JVk\WRiY3HzdIF{\S1|IHPs[YF3[WenIHHu[EDPui2lYYTlcolvKGSnZ4Lh[IF1cW:wMV2yOFcyOTV5MR?=
HCT116NHyydZZCeG:ydH;zbZMhSXO|YYm=MYqyNO69VQ>?Mo\NNlRpNIXr[JZqdmirYnn0d{B1cGViY3XscEBieG:ydH;0bYMhcW6mdXPl[EBjgSC\TGSyNFU>M4XaNVI1PzF|OEGy
L02MnHmRZBweHSxc3nzJGF{e2G7MkPHNlDPxE1?NXzTXld7OWh?MnqzdJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?=MVSyOFcxPjR4MR?=
A375NEjYWVNCeG:ydH;zbZMhSXO|YYm=M1vxXVIx|ryPNF7lS3czPGh?NEjBfWpz\X[ncoPld{BlcWOrdILpco9v\SCELXnu[JVk\WRiYYDvdJRwe2m|NYPzN3hHOjR4OUmxNVE>
HDPCM3z4VGFxd3C2b4Ppd{BCe3OjeR?=NH7PO282OML3TR?=M{TSTVI1cA>?NWOzNWVxcW6qaXLpeJMhVk9vaX7keYNm\CCjcH;weI9{cXN?Mo\1NlQ3OzR3OUO=
A549NVS0Rnd4SXCxcITvd4l{KEG|c3H5NY\XVmlGPTEEtV2=M3rGeFJpNYDDUYtUTE2VTx?=M2rkO5Bz\X[nboTzJJRp\SCqeYDv[IlxdG:rZDDEUmEh[2:wdHXueEBxcGG|ZTDpcoR2[2WmIHL5JINmeGijbH;jbJJwdWmwNWTNR4Y2OjR3OEixN|U>
 BV-2NVXpNop7SXCxcITvd4l{KEG|c3H5MXOyNO69VQ>?M1\4RVJpMWXzeZBxemW|c3XzJHVXNWmwZIXj[YQh[2i{b33heIlvKGW6dIL1d4lwdiCjbnSg[Ilt[XSrb36gc4YhfGinIH71Z4xm[XJiZX72[YxweGV?NYLCPFd4OjR3NUixNVg>
HT-29 MXPBdI9xfG:|aYOgRZN{[Xl?M1fEO|Ux|ryPMWW0PIg>MkXMZoxw[2u|IITo[UBieG:ydH;zbZMhcW6mdXPl[EBjgSCtYXXtdIZmem:uMWeyOFU1QTF5NR?=
A549NGHU[ZRCeG:ydH;zbZMhSXO|YYm=MYe1{txOMnXxNlRpM2i5SJN2eHC{ZYPz[ZMhPmYEoDjCT|ExODRyKT3pcoR2[2WmIHHwc5B1d3Orc9MgM1\SPVI1PTJ7OEex
MIA-PaCa-2MYnBdI9xfG:|aYOgRZN{[Xl?NXvlU3R5OjSqNF70cm1jdG:la4OgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGmwZIXj[YQh[nliYn;0bEBCNTR2M{[1OEBidmRicHHjcIl1[XinbB?=Ml7hNlQ2OTB7OUK=
Caki-1M{[zUWFxd3C2b4Ppd{BCe3OjeR?=NUHSV3dPOjEQvF2=NFfIb3YycA>?M1\mZYlvcGmkaYTzJHNEWC2rbnT1Z4VlKGGyb4D0c5Nqew>?M{fuOFI1PTB2Nkix
CLLMn24RZBweHSxc3nzJGF{e2G7MnrNNlXPxE1?MXWxbC=>NUDmdm43eGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?NX7CSlYxOjR2Nke2N|Q>
SGC-7901MmnPRZBweHSxc3nzJGF{e2G7NHqxZlMyOM7:TR?=MWeyOIg>M3LGXpBzd22xdHXzJJRp\SCFR1nJMYlvcGmkaYTl[EBk\WyuIHfyc5d1cCCrbjDTS2MuPzlyMTDj[Yxtew>?MUmyOFQ2PDR6OB?=
k1735MmDLRZBweHSxc3nzJGF{e2G7NGnSOWUzOOLCid88cS=>NWr6cGp6PGh?MlTSbY5pcWKrdIRCpHNidG2xbnXscIEucW6mdXPl[EBieG:ydH;zbZM>MVeyOFQ2OTFzNh?=
HaCaT M4nZZ2Fxd3C2b4Ppd{BCe3OjeR?=NGLLflAyODEQvF2=NITL[5IycA>?NGfGUYpjdHWwdIOgWXZDNWmwZIXj[YQh[XCxcITvd4l{KGmwIFjhR4FVKGOnbHzzNWfNfnN[OjR|NU[5PVc>
podocytesNGf1WVBCeG:ydH;zbZMhSXO|YYm=NFzsfVgzODEQvF2=NUfHWYpWPmh?NH\HcGFqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdGMn\RNlQ{Ozd5N{e=
 KBMWDBdI9xfG:|aYOgRZN{[Xl?NWXwV5B1PTEQvF2=M{[4XFI1cA>?NXXqRYR5cW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44>M3vsNFI1OzN5NEmy
 HepG2 MmTHRZBweHSxc3nzJGF{e2G7MlzqNVDPxE1?NGLHeXAzPGh?NVTrV2xMemWmdXPld{B3cW2nboTpckBkdGWjdnHn[UBk[XW|ZXSgZpkhVFCVMYWyOFMzPThzNh?=
fetal rat lung fibroblasts NW\E[Vl[U2mwYYPlJGF{e2G7NInjSYI5OM7:TdMgM3jhOVFpNG\iUFhqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>?NH\Vb4szPDNzNEGzOS=>
PDL fibroblastsNI\iPHBMcW6jc3WgRZN{[Xl?Mn[zPFDPxE4EoB?=NWKzeXcxOWh?M2\sN4lvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKhMXuyOFMyPDF|NR?=
MB49MlzJRZBweHSxc3nzJGF{e2G7NWi1ZYVZOjEQvF2=NEfyO48ycA>?MYHy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg>NI\MV2UzPDJ6MkSzNy=>
5637MVvBdI9xfG:|aYOgRZN{[Xl?MoDsNlDPxE1?MljZNYg>NGfhWpNz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh?NIPuR3YzPDJ6MkSzNy=>
A549 NWXZPWxRSXCxcITvd4l{KEG|c3H5MoX3NVAx|ryPMlvnOFhpNUDNXHdOe3WycILld5NmeyC2aHWgZZBweHSxc3nzJINifXOnZDDifUBxcXCncnnu[eKhM1;VV|I1Ojd{MkCx
MCC-2MULBdI9xfG:|aYOgRZN{[Xl?MXSyNEDPxE1?MnPwOog>NXjtb4xQTE2VTx?=Mnu1Zoxw[2u|IHnu[JVk\WRiYomgd5RifXKxc4Dvdolv\SCjcH;weI9{cXNiY3XscEBl\WG2aB?=NF\ETY0zPDJ4Mk[1PC=>
ADFNVTjdmI5SXCxcITvd4l{KEG|c3H5NH[3PZo1OM7:TR?=MXS2bC=>Mm\CbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK=Mnf0NlQzOjh{M{K=
 U373 Ml7iRZBweHSxc3nzJGF{e2G7MknwOFDPxE1?M2LCfFZpNWTjbIpNcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI>MYCyOFIzQDJ|Mh?=
RKO-HIPK2iNHXKbJNCeG:ydH;zbZMhSXO|YYm=M2rOTFQx|ryPMnPjOog>MkTxbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK=MVKyOFIzQDJ|Mh?=
HEC-1BNGDMR5NCeG:ydH;zbZMhSXO|YYm=M3[ySFIx|ryPM4L0clFpMn3JdoVlfWOnczDUVE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUm=MX:yOFIyOzN3OB?=
4T1MmHBR4VtdCCYaXHibYxqfHliQYPzZZk>NIm3WIMzNjVvMUFOwG0>MYG0bC=>NXjwc2Q5TE2VTx?=MVHy[ZNkfWW|IITo[UBkgXSxdH;4bYNqfHlib3[gOHQyKGOnbHzzJIlv\HWlZXSgZpkhW1CGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?=MWSyOFIxPjF4MR?=
OS MkDGRZBweHSxc3nzJGF{e2G7MlTENlDPxE1?MVy0bC=>M4TI[olvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDQSHQ>M3OydlI1OjB2OUO3
RPEMoDxRZBweHSxc3nzJGF{e2G7M1HJfFExOM7:TR?=MmHVOFhpNHXGeWtx[XK2aXHscJkhcW6qaXLpeJMhfGinIHPhcJBicW5vMTDhcoQhNTJiYXP0bZZifGmxbjDhd{B4\WyuIHHzJJRp\SClYYPwZZNmKGGldHn2ZZRqd25?M{HZN|I1OjB{MEWy
UD29aM1W4ZWFxd3C2b4Ppd{BCe3OjeR?=NUj6eXc1PTEQvF2=M1vVT|I1cA>?MUnpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=>MmPsNlQyQTB3N{S=
SH-SY5Y NXXqV4tjSXCxcITvd4l{KEG|c3H5NGTkfpYyOM7:TR?=MYWyOIg>MVrheJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe=MV:yOFE1PTR4Mx?=
HeLa MYrBdI9xfG:|aYOgRZN{[Xl?NIe2WpQyOC9{MN88US=>M1TvRVI1cA>?NXq1W3lUcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl?MnKwNlQyOzd{Nk[=
SCCVII Ml3JRZBweHSxc3nzJGF{e2G7NYXMNlRbOjYQvF2=M4DKcFFpM4q0NolvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmkM3\pc|I1OTJ4NE[0
RAW 264.7NInFVJNCeG:ydH;zbZMhSXO|YYm=NGjrSZkzOM7:TR?=NHz1XnoyQGh?NVHLcXo{cW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?=NWnad5dwOjRzMU[3NFc>
A549 NVG5[5JSSXCxcITvd4l{KEG|c3H5Mn\KNk42|ryPM1fDNVI1cA>?MUjk[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M>NILS[YkzPDFyMkWyNi=>
UM-SCC-10A MULBdI9xfG:|aYOgRZN{[Xl?Ml65OVDDvU1?NHHVNm0zcA>?M2j5ZZJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU>MWmyOFA6QDd3Mx?=
BGC-823M4jJVWFxd3C2b4Ppd{BCe3OjeR?=NYnjWop[OTBizszNMXSyOIg>Mnz3doVlfWOnczD0[ZRz[W6mcnnu[U1qdmS3Y3XkJIFxd3C2b4Ppd:KhMXGyOFA6QDVzMR?=
Nalm-6 M4DoeWFxd3C2b4Ppd{BCe3OjeR?=MW[yNO69VQ>?NHm1RY41cA>?MmXGbY5pcWKrdIOgZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbjDhcoQhWEGUUD2xJINt\WG4YXflM1\EeVI1ODN7OU[3
KHOS M2P0WWFxd3C2b4Ppd{BCe3OjeR?=NGrtRYM1OM7:TR?=NUTGVY9FOjSqMojRZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?=MUKyOFAzPTN4MR?=
G292M2ryfmFxd3C2b4Ppd{BCe3OjeR?=MlLmOFDPxE1?NHTJPW4zPGh?MWjicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8LiM2m2VVI1ODJ3M{[x
MG-63MWfBdI9xfG:|aYOgRZN{[Xl?MW[0NO69VQ>?MWeyOIg>M1\pXoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC=M2f3SlI1ODJ3M{[x
EBV-transformed B cellsMXfBdI9xfG:|aYOgRZN{[Xl?MofFNlDPxE1?NVLzcJpmOmh?M{nKZWROW09?NUnKNY1Q[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m|NFfFVmMzPDByOE[yPC=>
IM-9 BM4qxTGFxd3C2b4Ppd{BCe3OjeR?=NFvMVGUzOM7:TR?=NYPzOW1iOmh?MUXEUXNQNULtOJM2[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m|MXuyOFAxQDZ{OB?=
CNE1NXjZW2xsSXCxcITvd4l{KEG|c3H5NVzGNmJOOjEQvF2=MlvpOFhpNUjkcXpw[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN?NYLQ[JFWOjN7OEWwNlk>
CNE2MWrBdI9xfG:|aYOgRZN{[Xl?NXXEc|JDOjEQvF2=Mn\jOFhpNUG2cnh7[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN?MXeyN|k5PTB{OR?=
HL-60NYHuVFBZSXCxcITvd4l{KEG|c3H5NVHnfXYxPTEEtV2=Mof5NYg>MULEUXNQMnrNbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW=MkXONlM6PDh5NUG=
L929M2fUZ2Fxd3C2b4Ppd{BCe3OjeR?=NEj2WGEyNjJ34pETOeKh|ryPwrC=M{L0Z|I1cA>?NVS5SXlx[XWpbXXueJMhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7NWmxRXJnOjN7NEG3Olk>
JurkatMojPR4VtdCCYaXHibYxqfHliQYPzZZk>MnTVNu69VQ>?M{Xyd|RpM2qwfZJmfmW{c3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CEQsj3jZZRmdmmwIHTlZ5Jm[XOnIHL5JGhUNUGVQR?=MmTPNlM5QTZyNkG=
RAW264.7 MVvBdI9xfG:|aYOgRZN{[Xl?MYexNEDPxE1?NE\WXWEzPGh?MoD5[IVkemWjc3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDHRS=>M{L2R|I{QDJyMkCz
A431 MnPUT4lv[XOnIFHzd4F6M1nUPFQx|ryPMkTxNog>NI[ycWxjdG:la4Og[ol{\XSrbj3pcoR2[2WmIHPs[YF3[WenIH;mJINie3Cjc3XzJIFv\CCSQWLQNU\xRlluOjN6MECwOVg>
JurkatMlvaR4VtdCCYaXHibYxqfHliQYPzZZk>M3jIe|I2NTFyMN88US=>NH3aWXk3cA>?M3LsT4lvcGmkaYTzJJouTkFvQ13LMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NF\vS28zOzl|M{WzNi=>
COS-7 MXTGeY5kfGmxbjDBd5NigQ>?MV61NOK2VQ>?M2n3Z|I1cA>?MmHMZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>?NIPPXIozOzl|M{KwPC=>
CAL27NH3vU|dCeG:ydH;zbZMhSXO|YYm=MYCxNEDPxE1?M{TkW|JpNXTKWJoye3WycILld5NmeyCFdYKtUnB{NXKnZIXj[YQhfmmjYnnsbZR6KGK7IIXwJJRwKDlyJR?=M2HnXVI{QTF5M{m2
THP-1 Mn3qRZBweHSxc3nzJGF{e2G7M1XBPVExNTVyzszNMl76Nog>NGfudZlqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSC2cnnweI9tcWSnNXLMS2M{OjN7MECyPVk>
K562M2nSW2Fxd3C2b4Ppd{BCe3OjeR?=M4m2XFIx|ryPNWHtW3ZrPDiqMnLIbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhPC2PVR?=NY[zfolyOjN6N{[4NlY>
HL-60M{DL[mFxd3C2b4Ppd{BCe3OjeR?=Ml33NVAx|ryPM4TBTlI1cA>?MW\pcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBi[mmndHHu[UBlcXSncoDlcoV{yqB?MVGyN|g3PTd5OB?=
HeLa NHTFb2tCeG:ydH;zbZMhSXO|YYm=NFXxc4IzOM7:TR?=Ml\CNog>MVTpcohq[mm2czDEUW1RKGmwZIXj[YQh[XCxcITvd4l{NIfw[lMzOzh4M{m2Oi=>
U251MY\BdI9xfG:|aYOgRZN{[Xl?Ml\NNlDPxE1?MkTENlRpM2jrZYlvcGmkaYTzJINie3SrY3nuJIlv\HWlZXSgS|IwVSCyaHHz[UBienKnc4SgZY5lKGGyb4D0c5Nqew>?Mn3lNlM5OTZ6MU[=
HL-60NUK5fpdpSXCxcITvd4l{KEG|c3H5NGH4cpI2OML3TR?=MX20bC=>MXnicI9kc3NidHjlJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUmsJIFv\CCSQWLQJIlv\HWlZXSgZpkhPnN?NVLFZY5OOjN6MES3NFY>
Ec-109M3nYc2Fxd3C2b4Ppd{BCe3OjeR?=MUCxNEDPxE1?Mmj1OFhpNXfpVmxVemWycnXzd4V{KFCHLX3l[IlifGWmIFXjMVExQSClZXzsJIFxd3C2b4Ppdy=>NIDJPGgzOzd6Mk[0NS=>
RKONFGzWpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MnXFNVAh|ryPMYiyOIg>M2XLSolvcGmkaYTzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSClYYXz[YQh[nliRFHCNXzuU|BoOjN5NUiwOlQ>
T98GNUi2cHBUS2WubDDWbYFjcWyrdImgRZN{[Xl?MUOxMVExOM7:TR?=NFPG[WszPGh?MoLhbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?=M3\mV|I{PzZ7Mke1
JurkatNVjWWWp2S2WubDDWbYFjcWyrdImgRZN{[Xl?MVOxNFAuOjByzszNMXGyOIg>NXLI[ml{cW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMgNWH6O4M6OjN5M{K0PFE>
Molt-3 NF7TSWVCeG:ydH;zbZMhSXO|YYm=NEXQVJM2OM7:TR?=MUWybC=>NVXod49HemWmdXPld{Bu\WyjdH;ubY4ucW6mdXPl[EBieG:ydH;zbZM>M33leFI{PzJ3MEGz
hMSC12M13BOWFxd3C2b4Ppd{BCe3OjeR?=M325cFExOM7:TR?=M1;XflRlNEnhTIdqdmirYnn0d{Bwe3Snb3flcolkKGO3bIT1doUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDjZYxkcW[rY3H0bY9vNYXuWYs3OjN4NUe4NlI>
HM7 M1zYO2Fxd3C2b4Ppd{BCe3OjeR?=NWP0VnY6OjEQvF5CpC=>MlWyNYg>M3rkRoJtd2OtczDhdIlkfWyjcnXuJGEh[WOndHH0[U1qdmS3Y3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDQRXJRKGOuZXH2ZYdmMoW2NlM2QDN2MUK=
Hep-2 MljCRZBweHSxc3nzJGF{e2G7MlT0NlDPxE4EoB?=NX3zVHg1OjSqNWjofm9STE2VTx?=MX3hcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?=MViyN|U5ODB|Mh?=
HSCsNGDnS5lCeG:ydH;zbZMhSXO|YYm=M1fUV|Ux|ryPMmrYNlRpNVXuSY1nTE2VTx?=NHPKW4lqdmirYnn0d{BvcWyxdHnubYIucW6mdXPl[EBFVkFiZHHtZYdmKGmwZHnjZZRm\CCkeTDQRXJRKGOuZXH2ZYdmNF\BeW8zOzR7OUi3OC=>
HL-60 M3vGVWN6fG:2b4jpZ4l1gSCDc4PhfS=>MWSyNO69VcLiNUH6RYpiOjSqNXTLRm5nemWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2NIC0epYzOzR7NES4NC=>
HAM2DZNWFxd3C2b4Ppd{BCe3OjeR?=NIj0Wlc2OM7:TR?=NWe5[I1YOjSqMkPtd5VxeHKnc4Pld{B1cGViY3zlZZZi\2Vib3[gVGFTWCCjbnSgZ4F{eGG|ZT2zMEAuPyxiYX7kJE06KGmwZIXj[YQh[nliYn;yeIV7d22rYj;TRWhCMmLjNlM1PzV7NU[=
C666-1MYDBdI9xfG:|aYOgRZN{[Xl?NIKwUIg2OM7:TR?=MUCyOIg>M2PGdJN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>?NHvSS|EzOzR5NUm1Oi=>
Hepa1-6MmDCRZBweHSxc3nzJGF{e2G7NWHHSXRxPTEQvF2=MlXJNog>MYjpcohq[mm2czDjeZJkfW2rbjDhcoQhemW|dnXyZZRzd2xvaX7keYNm\CCjcH;weI9{cXN?NWWwOmZ5OjN2NE[3OVM>
PLC/PRF/5cMkL2RZBweHSxc3nzJGF{e2G7MWG1NO69VQ>?Mo\4NYg>MmXsdJJmfmWwdIOgZZBweHSxc3nzJJRzcWepZYLl[EBjgSCFSV6=MVGyN|Q{QDh{NB?=
HCT116MX\BdI9xfG:|aYOgRZN{[Xl?NFXkXmcyODEQvF2=MnTqNU42cA>?NEPrUIdqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh?NEPMNVgzOzd2NEO1Ny=>
HCECNUnD[mF5TnWwY4Tpc44hSXO|YYm=M4nNO|Ux|ryPM1zMZ|czcA>?NUXBWm9STE2VTx?=MkfLdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=>NGTLZWczOzd2MkCxNS=>
Primary rat cerebral cortical neuronsMV;BdI9xfG:|aYOgRZN{[Xl?MlizNVAx|ryPNX;qfmw1OWh?NYLXO|Q{eHKndnXueJMhS2RvaX7keYNm\CCjcH;weI9{cXNiYX7kJINmdGxiZHXheIg>MXSyN|c1OTNzNx?=
MDA-MB-231 NFfVT4JCeG:ydH;zbZMhSXO|YYm=MVKyOe69VQ>?NUf1TIpUOjSqMWrhZpJw\2G2ZYOgZ5l1d3SxeHnjbZR6KGGwZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMh[W6mIGDBVnAhcW6mdXPl[EBjgSCUZ{O=MUiyOVM{PzV2NB?=
NLRP3-Tet-on-MC/9 NITkUmVCeG:ydH;zbZMhSXO|YYm=NEfLPG0yOC12MN88US=>Mnf2NVJpM1vNeIF1fGWwdXH0[ZMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JGNCWFNvYYPzc4Nq[XSnZDDOUHJROyCvdYThcpR{KGmwIITo[UBV\XRvb36gd5l{fGWvMknINlM4ODN|OEm=
KNS42 NW[zUWszSXCxcITvd4l{KEG|c3H5NIO0S|k2OM7:TR?=MofYNYg>NUe2TG0zemWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36=NHmwWZczOzZ7MUG0OS=>
MCF-7 NVXFfoZ6SXCxcITvd4l{KEG|c3H5MU[yNO69VcLiMk\MO|JpMUjpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?=MVGyN|Y4PTZ2Mx?=
hCMEC/D3 NIi4WohCeG:ydH;zbZMhSXO|YYm=Mm\HNlXPxE1?M2PNTVczcA>?NGftV21z\WS3Y3XzJGx1gEFiaX7keYNm\CCjcH;weI9{cXN?NIHmV4gzOzZ4NUG5PC=>
JurkatMnrKRZBweHSxc3nzJGF{e2G7MYmxNk42NTVyzszNM4fwNVFpNET3Rndld3OnIHTldIVv\GWwdHz5JJN2eHC{ZYPz[ZMhW1CKLXnu[JVk\WRiUHHyMVQh[2ynYY\h[4UtKFCDUmCgZ4xm[X[jZ3WsJGRPSSCocnHncYVvfGG2aX;uMEBidmRibH;zd{Bw\iC4aXHibYxqfHl?M2nqOFI{PDR{OUe2
CNE-1NWja[FRFSXCxcITvd4l{KEG|c3H5NFr2eWgzOM7:TdMgMoCzNlRpM4PSeYlvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi=MXKyN|QzPjh3MB?=
HONE-1MXTBdI9xfG:|aYOgRZN{[Xl?MoDuNlDPxE4EoB?=NEfkWIQzPGh?MV7pcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSqM2L0NFI{PDJ4OEWw
astrocytes cellNX3t[IZFSXCxcITvd4l{KEG|c3H5NYfKZnlbPDEQvF2=MWS2bC=>MmfndoVlfWOnczDlZZJtgSCjcH;weI9{cXNiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5mNEW3PHIzOzRzMUe3PC=>
U-937NYLkeItRSXCxcITvd4l{KEG|c3H5MVqxNO69VQ>?MYCzNI1qdg>?NIPPe4hxemW4ZX70d{BVVkZvaX7keYNm\CCwZXPyc5B1d3Orcx?=NGnsfWQzOzRzMEe0PC=>
MDA-MB-231MXTBdI9xfG:|aYOgRZN{[Xl?NXrTXHdrOTByzszNNY\0[3VCOWh?NF3QcllqdmirYnn0d{B{\W6|aYTpfoF1cW:wIITvJHRTSUmOIIXwc44hVVSGSDDkc5dvNXKnZ4XsZZRqd25?NF3TZlIzOzRyOESyPS=>
HeLa NVPPPIhOSXCxcITvd4l{KEG|c3H5MkXINVAx|ryPNGTWXW4zcA>?M4XaOYJtd2OtczDKVnMuOTViSX7keYNmeyCDcH;weI91cWNiQ3XscEBF\WG2aB?=MVuyN|M1PDB2NR?=
Ec109MoHVRZBweHSxc3nzJGF{e2G7NHP3OHUyOM7:TR?=NXrBSG9vPmh?MnS4Zoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44>MoPZNlM{Ozh3Nki=
H460 NWPPZXZXSXCxcITvd4l{KEG|c3H5MlrBNVDPxE1?NWfJe5A{Pmh?NFO0bXBjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>?MlLnNlM{Ozh3Nki=
HeLa NIWwUm5CeG:ydH;zbZMhSXO|YYm=MX[1NO69VQ>?NF;iXoYyNjWqMl3mZYJzd2ejdHXzxsBEcGyjbYnkbYEucW6mdXPl[EBieG:ydH;zbZM>MmHBNlM{ODN6MES=
SK-HEP1NHXEd|RCeG:ydH;zbZMhSXO|YYm=MWWxNFDPxE1?NG\tTFcycA>?MmHSbY5pcWKrdIOgR5JVOSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtO{whNThuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOnMVqyN|MxOjZ3MB?=
QGY7701MUjBdI9xfG:|aYOgRZN{[Xl?M2iyXFI2|ryPNHqyfmIyNjWqMXLpcohq[mm2czDhZ4N2dXWuYYTpc44hd2Zic4XiMWcyKHCqYYPlJIlv\HWlZXSgZpkhTE:[IDugdZVmemOndHnuMYKyN|I1ODB4MR?=
HepG2NH7oN41CeG:ydH;zbZMhSXO|YYm=NGm5ZpgzOM7:TR?=MUGzNI1qdg>?Mn;tbY5pcWKrdIOgeIhmKGWwaHHuZ4VlKGOnbHyg[IVifGhiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKGGyaXflcolvKGGwZDDUVmFKVA>?NG\FZWwzOzJ{NEKzPS=>
U87 M17ON2Fxd3C2b4Ppd{BCe3OjeR?=NX:2VYRCOjYQvF2=MUGybC=>NF:2PYZl\WO{ZXHz[ZMhcXOxbHnxeYlzcXSrZ3XubY4hMEmVTDmtbY5lfWOnZDDhdI9xfG:2aXOgZ4VtdCCmZXH0bEwh[nW2IH7veEBv\WO{b4TpZ{Bk\WyuIHTlZZRpNH3ENYIzOzJ{OU[yOi=>
HSC-2NXjTWXVNSXCxcITvd4l{KEG|c3H5M3zIfFI2NzVyzszNMW[xbC=>NIPKbJZqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=>NVPTdpA5OjNzNUWyOFg>
HSC-4NVfiSZRvSXCxcITvd4l{KEG|c3H5NGnJTGUzPS93MN88US=>MWqxbC=>NW\wZWcxcW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk>MUeyN|E2PTJ2OB?=
CL-1NWH6cGd6SXCxcITvd4l{KEG|c3H5MorsNlDPxE1?MX:xbC=>NIG3eGdjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSqNGD6Z2szOzF|MUe4Ni=>
MELNVHKZ4EySXCxcITvd4l{KEG|c3H5NEDvem0zOM7:TR?=NWfu[WxEOjSqMmXoSG1UVw>?MX3pcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{NHPacnYzOzBzNEi4Oy=>
Bel-7402 M4DGbGNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?=M3[zO|Ux|ryPM1LsfVJpM2HGd4lvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM>M2XmN|I{ODB6N{Sy
Eca-109M{X6XmFxd3C2b4Ppd{BCe3OjeR?=NI\tSYYzPc7:TR?=NY\sb4oyOzCvaX6=NGjTb49qdmirYnn0d{BDUi2EMUGtbY5lfWOnZDDj[YxtKGSnYYToM2TNS|I{ODd4OU[3
MELMoS4RZBweHSxc3nzJGF{e2G7MXKyNO69VQ>?MlPWNYg>NFPEfINFVVORM17aN4lueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN?M{OzZlI{ODF2OEi3
Bel-7402 NXf5fZN4SXCxcITvd4l{KEG|c3H5NWPOfVJ2PTEQvF2=NYPMT5JvOmh?MnXobY5pcWKrdIOgVGNGNWmwZIXj[YQh[W6xaXvpdy=>M3n3R|I{ODB6N{Sy
L929NHHyV5NHfW6ldHnvckBCe3OjeR?=Ml2zNk42|ryPMV:xbC=>NHnxbY9qdmO{ZXHz[ZMhWkmSMTDlfJBz\XO|aX;uJIFv\CCneHHj[ZJj[XSnZDDUUmbPuS2rbnT1Z4VlKG2rdH;jbI9v\HKrYXyg[Jl{\nWwY4Tpc44h[W6mIGLPV{Bxem:mdXP0bY9vNIradGUzOzByMEWxPC=>
RCC M1vSZWNmdGxiVnnhZoltcXS7IFHzd4F6NV3wVGliOTByzszNM2nucVI1cA>?M4TK[5Jm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK=NEHQfFQzOjl7MUS5OC=>
NB2a/d1MVnBdI9xfG:|aYOgRZN{[Xl?M1fBbFExOM7:TR?=NYLTdGdmPzKqNIXLO5lifHSnboXheIV{KHO2YYXyc5Nxd3KrbnWtbY5lfWOnZDDjZZNx[XOnIHHjeIl3cXS7LDDQRXJRNCCjbnSgeIF2KGOuZXH2ZYdmNIHubIwzOjl6OEW0NS=>
T cellNHzkcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvWOlI1OjVvMUCw{txONX\sOnc5OjSqM1;1TYRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>?MU[yNlk5OjV|OB?=
K562M331UmFxd3C2b4Ppd{BCe3OjeR?=NWTvdZVEOTByzszNMYGxbC=>NEDZOGZjdG:la4OgRYJvd2KjdnnzZ5VuyqCILXnu[JVk\WRiYYDvdJRwe2m|Mn6zNlI6PzJ|N{K=
Jurkat M3;NR2Fxd3C2b4Ppd{BCe3OjeR?=NHmyXG41OM7:TR?=NHvEbpAycA>?NWnjXpA5[WKxbHnzbIV{KE[jc1ytbY5lfWOnZDDjZZNx[XOnIHHjeIl3[XSrb36gZY5lKGOnbHyg[IVifGh?NETUTYszOjl2MkezPC=>
BGC-823M3fWW2Fxd3C2b4Ppd{BCe3OjeR?=MXWxNFDPxE1?MV[xbC=>Mlr3dIFzfGmjbHz5JJJme2O3ZYOgZ4VtdHNiYXfhbY5{fCCmYX3h[4Uhd2ZiZHHp[JpmcW5?NYK5XGg3OjJ7Mk[1OFU>
Hep3BNFX6TmxCeG:ydH;zbZMhSXO|YYm=NVnlNI54PTEQvF2=M2W2O|FpMm\lZoxw[2u|IHHwc5B1d3OrczDpcoR2[2WmIHL5JGhGT0O|NYq2UnJ2OjJ7MkOxOVQ>
LLC-PK1MX\BdI9xfG:|aYOgRZN{[Xl?MmX6NlDPxE1?NUjEclhiOWh?NYXndXVMeHKndnXueJMh[2m|cHzheIlvNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gRZRoPSxiYnXjcIlvNTFuIHHu[EBCfGdzMjDwdo91\Wmwcx?=NVrNNm9{OjJ6OU[wN|c>
A549MUPBdI9xfG:|aYOgRZN{[Xl?NUG1cJNFPTEQvF2=M1TCfFFpNILZc5JjdG:la4OgeIhmKEKDST3pcoR2[2WmIHHwc5B1d3Orc9MgNYTOSHNMOjJ6OEeyNVU>
SGC-7901 NVq3SZdYSXCxcITvd4l{KEG|c3H5M33QNlEx|ryPMXWyOIg>NH;td41qdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>?MXKyNlg1QDV7Nx?=
DM6NGjPeZRCeG:ydH;zbZMhSXO|YYm=NGTYRXIyODEQvF2=MVG3Nog>MmXVZoxw[2u|IHLveIghTTKILUGgZY5lKEV{RoTyMY1m\GmjdHXkJIN6fG:2b4jpZ4l1gQ>?NGn0S|AzOjh{NUOyPC=>
MCF-7, MDA-MB-468, Caco-2Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;uVHBlPTEQvF2=NYPrRY9IPDiqNHPBdlhqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4>M1i1XFIzQDByOU[4
A2750 NETj[4hCeG:ydH;zbZMhSXO|YYm=NIniZ5UzOM7:TR?=M1m4SVJpM1Lqe2ROW09?NFP2SZNjdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?M1;X[lIzPzh2M{[z
U87 M{m5PWFxd3C2b4Ppd{BCe3OjeR?=NWPiWnZ2OjEQvF2=Mme4NlRpNH\vU3Fz\WS3Y3XzJJRp\SCjcH;weI9{cXNicnH0[UBqdmS3Y3XkJIJ6KFCOQVK=NI\CfJEzOjd5OEe4NC=>
HT1080M2rOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT5SpA2OM7:TR?=NIS4c4g4\A>?NIWxeW1qdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBk[XW|ZXSgZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIFTDRUBidmRiT13QNELP[YczOjd2MEm4OC=>
A549 MWrBdI9xfG:|aYOgRZN{[Xl?NGjkToQ2OM7:TR?=NUjDeVVkOmh?MUTwZZJ1cWGubImg[IVkemWjc3XzJJNw\Gm3bTDz[Yxmdmm2ZT3pcoR2[2WmIHHwc5B1d3Orcx?=Ml\ZNlI4OjF6MES=
Primary OPCMmnwRZBweHSxc3nzJGF{e2G7NVi2R4FtOc7:TR?=NWPocmRCPmhxMkToNEHWRZNz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO=M4jqUlIzPzB5M{i1
PMNsM3HxN2Fxd3C2b4Ppd{BCe3OjeR?=NWTFN5gzPDEQvF2=M2DTUlZpMkHrSG1UVw>?M33Rc5JmfmW{c3XkJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CClYYPwZZNmNTNidH:gcoVieiC4ZXjpZ4xmKGyndnXsdy=>NWXpZY1QOjJ4OUK1O|c>
A549 NV7rW41zSXCxcITvd4l{KEG|c3H5M{jRV|Ux|ryPMl70NYg>MX7wdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBD[W:qdX;zbYRmKEl?MnvuNlI3QDd4M{W=
AGSM1\NNGFxd3C2b4Ppd{BCe3OjeR?=Mmf0NlDPxE1?NH;KVHQyOmh?MXLpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=>NGTyRXEzOjZ6N{O5PC=>
shC9 MkfoRZBweHSxc3nzJGF{e2G7MWCxNO69VQ>?Ml;TNVZpMn7rZox2dnS|IGPITEBmgHC{ZYPzbY9vKGmwIIPoR|kh[2WubIOg[Zhxd3OnZDD0c{BmcXSqZYKgVGEhd3JiTGDDMXqyNlY1OTB7NB?=
primary MEFsNHrqW4JHfW6ldHnvckBCe3OjeR?=NGjqNpIyOmh?NV;YfJNlyqCrbnPy[YF{\XNiZYTvdI9{cWSnLXnu[JVk\WRibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBl\XCxbHHybZpifGmxbh?=MUGyNlYyOzd4Nx?=
3T9 MEFsM13RUWZ2dmO2aX;uJGF{e2G7NV7kRo5COT[qMnr1bY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ>NHrDfZQzOjZzM{e2Oy=>
3T9 MEFsMnHHSpVv[3Srb36gRZN{[Xl?MWSxPIg>M4WyWZVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>?MkLaNlI3OTN5Nke=
MDA-MB-231 MkniRZBweHSxc3nzJGF{e2G7Mm[yNlDPxE1?MkX5OIQ>NELlfW5z\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl?Mn7GNlI2QTN2NEG=
C6 NIDpbplCeG:ydH;zbZMhSXO|YYm=MUKxNO69VQ>?MoPBNlRpNVnjWJR7[myxY3vzJJRp\SC|dYDwdoV{e2m4ZTDl[oZm[3Rib3[geIhmKHCncITp[IUhd25idnnhZoltcXS7MlrhNlI2QDh7OEC=
HL-60 MnLtRZBweHSxc3nzJGF{e2G7MnfUNVAx|ryPNGjSSJgzPGh?NXnMfJpzcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU>M3r1TlIzPTR4Nk[5
HL-60MUnBdI9xfG:|aYOgRZN{[Xl?MnXONVAuQDEQvF2=M{LqN|RpMWLpcohq[mm2czDUS2hSNWmwZIXj[YQh[2WubDDhdI9xfG:|aYRCpC=>MlrUNlI2OjN{Mkm=
BCCMk\vRZBweHSxc3nzJGF{e2G7MU[1NO69VQ>?MkTmNYg>NWjsfVQzcW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?=MViyNlUyQTR|Nh?=
RAW 264.7M{nPU2Fxd3C2b4Ppd{BCe3OjeR?=MWK1NE8yODEQvF2=M1LIWFFpMXLjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1eyCGT16tbY5lfWOnZDDyVm5CKGOuZXH2ZYdmMWGyNlQ6OTR{Nh?=
K562NEn1bmVCeG:ydH;zbZMhSXO|YYm=NIrmTnkzPc7:TR?=M3nVclJpNVP1TJZxeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3:teJJm[XSvZX70JJdqfGhiYX31doVve2mwIFegZY5lKFSUQVnMM4DMSFIzPDh|N{e3
SGC-7901MUfBdI9xfG:|aYOgRZN{[Xl?NWLoZ2VwOjBizszNxsA>NH;MPZAzcA>?M{fC[oF1fGWwdXH0[ZMhUDKRMtMgc5IhXE6IIN8xMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXNiYYOge4VtdCCjczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=>NUXnOXJ{OjJ2N{G1PFk>
PC3MmjzRZBweHSxc3nzJGF{e2G7MX2xNO69VQ>?NGjscI01cA>?M3;NbYNwfW62ZYLzJIZt[X[xY3;4bYQucW6mdXPl[EBk[XOyYYPlMZJmdGG2ZXSgZZBweHSxc3nzM1rpTVIzPDdzOUe0
SMMC-7721MV7BdI9xfG:|aYOgRZN{[Xl?NF3ReIg2OM7:TR?=M4PTdVQ5cA>?MlG3ZZR1\W63YYTld{BwXFJvaX7keYNm\CCjcH;weI9{cXN?NHT1VZkzOjR4NUizNy=>
HeLa NFjaNVJCeG:ydH;zbZMhSXO|YYm=M{juU|UxyqEQvF2=M{nqVFQwQGh?NUi1[25XcW6qaXLpeJMhW1SVLXnu[JVk\WRibHH0[U1xcGG|ZTDhdI9xfG:2aXOg[ZZmdnS|NY\BW5JOOjJ2NkC1NFQ>
HeLa NHLCTYpCeG:ydH;zbZMhSXO|YYm=NU\CfpRHPTEEoN88US=>MnmzNYg>NVzXfFNQe3WycILld5NmeyC2aHWgSnJCWC2rbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBidm6neHnuJHYheG:|aYTpeoUh[2WubIO=M3r0eFIzPDR7NESw
T47D M3XsOmFxd3C2b4Ppd{BCe3OjeR?=MlTWNVAx|ryPM{The|FpNWTkbIVy[myxY3vzJJRp\SCpZX7ldoF1cW:wIH;mJGUu[2GmL1PUSlIh[nliU2TTMkPHNlI1ODFzNki=
HeLa NHvEWJNCeG:ydH;zbZMhSXO|YYm=MmTGN|DPxE1?MoLtOIg>NW\wUHpSyqCrbnPy[YF{\XNidHjlJIdmdmW{YXygZ4VtdCC4aXHibYxqfHliNEigbEBi\nSncjDwbI91d2S7bnHtbYMhfHKnYYTt[Y51yqB?NFK5S24zOjN7NEK0PC=>
HCCNXyyU4pkSXCxcITvd4l{KEG|c3H5MXyyNEDPxE4EoB?=NI\UdmMzcA>?MUfheJRmdnWjdHXzJJRp\SCGSFGgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFCDUmC=NIfQZ2YzOjN2MkezNi=>
mESCsNYe2OY1zSXCxcITvd4l{KEG|c3H5MVGyMlXPxE1?NHm3VHkzcA>?M3HwV4lvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;uNWPOWGt4OjJ{OEWyO|Q>
EMT-6 M1vtSGN6fG:2b4jpZ4l1gSCDc4PhfS=>NHnoUoIyODEQvF2=M{HEfVFpNXrFWJRweGG{dHnhcIx6KGKub3Pr[YQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IIPpdoFu\XOrbnW=MY[yNlI2OTl{MR?=
MCF7M1nwS2Fxd3C2b4Ppd{BCe3OjeR?=M2\XXVUxyqEQvF2=NX;JZZVHOWh?NGDpcYlqdmirYnn0d{BRSSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtPUwh[W6mIIDvcJkpSUSSLYLpZo9{\SlicH;sfY1memG|ZR?=NHnCU5AzOjJ{M{O0OS=>
K562NEHpWWVCeG:ydH;zbZMhSXO|YYm=MmLvNlAh|ryPwrC=Ml7GOFhpMmT2SG1UVw>?NUjFUYVI[myxY3vzJIxieGG2aX7pZk1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZidnnhZoltcXS7IHHu[EBieG:ydH;zbZMhcW6mdXP0bY9vMom5NlIzOTZzNUi=
Molt4-hygMUnBdI9xfG:|aYOgRZN{[Xl?MnHFNVDPxE1?NGTHVFExNjWqNVywXGhu[myxY3vzJIZiem6nc3;sMYlv\HWlZXSgZ4F{eGG|ZT2zMYxqc2ViYXP0bZZqfHl?NV:wNngyOjZ{N{W4NVE>
HeLaNV[4cI9xSXCxcITvd4l{KEG|c3H5M4TUelEx|ryPM1W1NVAvPWh?M1u4dYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHSqZTDjc41jcW6nZDD0doVifG2nboSge4l1cCCpb33pd4lvKE5iYX7kJHRTSUmONYPEXXlGOjJzN{m2OlE>
Jurkat TM3O5[2Fxd3C2b4Ppd{BCe3OjeR?=NV:2WlhzOzEQvF2=NYLHfIdWOC53aB?=M2XWTWROW09?Mn33Zoxw[2u|IITo[UB7cXKjbT3pcoR2[2WmIHHwc5B1d3Orcx?=NUKzcIF[OjJzNUm4PVg>
NeutrophilM1LiSmFxd3C2b4Ppd{BCe3OjeR?=MWiyNO69VQ>?M{PkSlAvPWh?NXzTSVZx[XS2ZX71ZZRmeyC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5Qhd2ZiTXHSNS=>M1T6eVI3OTl4OES0
HCT116M3;l[GFxd3C2b4Ppd{BCe3OjeR?=NEj5U3U2OMLizszNMl[1Nog>Mo\RdoV3\XK|ZYOgd5lv\XKpaYP0bYMh[XCxcITvd4l{KGWoZnXjeJMhd2ZiY3Xs[YNwgGmkIHHu[EBPWENvMUdCpC=>MYGyNlE2QTd3Mh?=
MDA-MB-231 MVrBdI9xfG:|aYOgRZN{[Xl?NH\3Rm0zNjVvNz61{txOMY[ybC=>NVK5RoNwcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigc4YhVUSDLV3CMVI{OSClZXzsd{BqdmS3Y3XkJIJ6KFOGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?=MWKyNlEyPTV{Nh?=
LNCaPNFLwSHhCeG:ydH;zbZMhSXO|YYm=M{PzNlQx|ryPNGnQR3czcA>?NUPBRVFucW6qaXLpeJMh[nW2ZXnuJIlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?NEHmNHMzOjFzNEe2OC=>
MB231MXnBdI9xfG:|aYOgRZN{[Xl?MVexNFDPxE1?NF7sNWcycA>?NHfOTo9FVVORMl;aZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>?NUjhZm93OjJzMUK5OFA>
HCC38 MmDCRZBweHSxc3nzJGF{e2G7NFj5blEyODEQvF2=MkS3NYg>MlrISG1UVw>?MX;hZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9vMk\uNlIyOTJ7NEC=
MDA-MB231M37o[mFxd3C2b4Ppd{BCe3OjeR?=M3\aeVUxyqEQvF2=NIHXOIwzPGh?MkTTSG1UVw>?NXSzeXJU[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>?NFzvWowzOjFyMUOzOS=>
LNCaPMnXBRZBweHSxc3nzJGF{e2G7M2nES|UxyqEQvF2=NHXITJUzPGh?Ml\HSG1UVw>?M{\DVoFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg>MnHENlIyODF|M{W=
HCT116NEHtfFZCeG:ydH;zbZMhSXO|YYm=NYjEZmRrPTEEoN88US=>NXrr[IVLOjSqM4HDTWROW09?MnrCZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>Mmq3NlIyODF|M{W=
Ishikawa NFXObZVCeG:ydH;zbZMhSXO|YYm=M{LpVlI2|ryPM1vjR|I1cA>?M3\QRZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiYYDvdJRwe2m|IHnu[JVk\WRiYomgRoFnKEFzMXuyNlA5QDlzOB?=
 YD-8 MUXBdI9xfG:|aYOgRZN{[Xl?M3PFOlExOM7:TR?=NGHWOXgycA>?MmP2bY5pcWKrdIOgVGxGVy2rbnT1Z4VlKGGyb4D0c5Nqew>?NH7ydYkzOjB6NkG4Ny=>
eosinophil MYLBdI9xfG:|aYOgRZN{[Xl?NUnkU21UQTEQvF2=NWn5XI9JOjSqMVHpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?=NFTmS2YzOjB5OUOzOC=>
L929NH3PSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX6WFkzNjYQvF2=M3u4R|I1cA>?MWDpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwMZA{QCCjbnSgUmYu|rqEIITvJIF2\22nboSgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6M4rkeFIzODJ5MEm3
YD-8 MkP3RZBweHSxc3nzJGF{e2G7NETFeZoyODEQvF2=NWfSdFJxOWh?MV;icI9kc3NidHjlJGdUNUiFbD3pcoR2[2WmIHHwc5B1d3Orcx?=MkTjNlIxOjByN{i=
HBxM{XXbWFxd3C2b4Ppd{BCe3OjeR?=NVLyXZJzOjYQvF2=M{XFeFQ5cA>?MWTEUXNQMojodoVlfWOnZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhOy2PQR?=M4O5cVIzODJyMEe4
U937 NYDVU3JRSXCxcITvd4l{KEG|c3H5MkfwOVDDqM7:TR?=MWmxbC=>MUPpcohq[mm2czDISk1qdmS3Y3XkJIFxd3C2b4Ppd:KhNXT6RZM{OjF7OUi3N|E>
HL60M33oNGFxd3C2b4Ppd{BCe3OjeR?=MkPIOFDPxE1?M2TxRVQxdWmwM{fxSWROW09?NX7PVmZb[myxY3vzJGJPTENiY3;tdI92dmS|IHnu[JVk\SCneIDvd5Vz\SCxZjDwbI9{eGijdHnkfYx{\XKrbnWgZY5lKESQQTDmdoFodWWwdHH0bY9vMkj0NlE6QDN{OU[=
M-14NYjL[3FKSXCxcITvd4l{KEG|c3H5MkX1NlXPxE1?Mo\2NE42cA>?MV5CpIlvcGmkaYTzJIJwfGhidHjlJINzfWSnIHX4eJJi[3RvIHHu[EBkd22yb4Xu[E1qdmS3Y3XkJIFxd3C2b4Ppdy=>NFHzXXAzOTl3NEm1PS=>
SK-BR-3MmLSRZBweHSxc3nzJGF{e2G7M3nLNlUxyqEQvF2=NHrq[FIzcA>?NGP5bmtjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44>MlSyNlE6ODF|OE[=
MDA-MB-468MmTPRZBweHSxc3nzJGF{e2G7NVXVdZU6PTEEoN88US=>NF24No4zcA>?MWnicI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36=NUXG[oV7OjF7MEGzPFY>

... Click to View More Cell Line Experimental Data

In vivo
Features A key compound for apoptosis studies.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Slee EA, et al. Biochem J, 1996, 315 (Pt 1), 21-24.

[2] Shimizu T, et al. Leukemia, 1997, 11(8), 1238-1244.

view more

Chemical Information

Download Z-VAD-FMK SDF
Molecular Weight (MW) 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 93 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol 24 mg/mL warming (51 mM)
DMF 84 mg/mL
* Z-VAD-FMK will racemize in DMSO, water and ethanol.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-

Customer Product Validation(2)


Click to enlarge
Rating
Source Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck
Method Western blot
Cell Lines SaOS2 human osteosarcoma cells
Concentrations 10 uM
Incubation Time 24 h
Results To investigate the effect of the caspase inhibitor zVAD-fmk on the icaritin-induced apoptosis, it performed Western blot analysis to evaluate the levels of cleaved caspase-3. It found that the caspase inhibitor zVAD-fmk could decrease the icaritin-induced caspase-3 expression in the zVAD-fmk+icaritin-treated group compared to the icaritin-treated group (P<0.05).

Click to enlarge
Rating
Source Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck
Method Western Blot
Cell Lines Gastrocnemius muscles
Concentrations 1.5 mg/kg
Incubation Time 5、12 days
Results Results from western blot analyses showed that ATF2 levels were higher in the tumor-bearing animals than in the healthy controls. ATF2 levels in the groups treated with CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk, at either 5 or 12 days after inoculation, were lower than in the CC group (treated with PBS).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Caspase Products

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Belnacasan (VX-765)

    Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM in a cell-free assay. Phase 2.

    Features:A potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

  • PAC-1

    PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

    Features:The first small molecule known to directly activate procaspase-3 to caspase-3.

  • Apoptosis Activator 2

    Apoptosis Activator 2 strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells.

  • Tasisulam

    Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us